Clinical Trial: Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07398638) titled 'Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study' on Jan. 28.

Brief Summary: This is a prospective, multicenter, open-label Phase Ib/II clinical study designed to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of lisatoclax in combination with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Study Start Date: Feb. 28

Study Type: INTERVENTIONAL

Condition: Diffuse Large B Cell Lymphoma (DLBCL)

Intervention: DRUG: R-CHOP

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

DRUG: POLA-R-CHP

Polatuzumab vedoti...